Affimed Therapeutics Reports Positive Phase 1 Data for Hodgkin's Treatment


Affimed Therapeutics is a research partner of the Leukemia & Lymphoma Society. The major blood cancer charity co-funds the AFM13 research program as part of its Therapy Acceleration Program.

At the most recent annual meeting of the America Association for Cancer Research, Affimed presented data from a Phase 1 trial of a novel immunotherapy treatment, currently known as AFM13.

AFM13 is designed for patients with Hodgkin's lymphoma (HL) for whom currently available treatments have failed. AFM13 is a so-called bispecific antibody that directs natural killer cells to kill CD30-positive cancers like Hodgkin's.

The Phase 1 trial showed that AFM13 met its primary endpoint and demonstrated that AFM13 can be administered safely. It also showed favorable activity in terms of tumor response.

A Phase 2 study investigating optimized dosing will be initiated later this year.

The cure rate for Hodgkin's lymphoma is very high, but for about ten percent of patients, no conventional therapies work, leaving an unmet need in

Source: LLS

LymphomaInfo Social